#1 Clinical Trials Search in Europe

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis Who Have Not Responded Well to Previous Biologic Treatments

1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called Risankizumab on individuals with Psoriatic Arthritis. Psoriatic Arthritis is a condition that causes joint pain and swelling, often occurring in people who have psoriasis, a skin condition characterized by red, scaly patches. The study will compare the effectiveness of Risankizumab, which is given as an injection, to a placebo. Risankizumab is also known by its code name, ABBV-066.

The purpose of the study is to evaluate how well Risankizumab works in reducing the signs and symptoms of Psoriatic Arthritis. Participants in the study will receive either Risankizumab or a placebo through injections. The study will monitor the participants over a period of time to assess improvements in their condition. The main goal is to see if participants achieve a significant reduction in their symptoms by the 24th week of the study.

Throughout the study, various health assessments will be conducted to measure changes in the participants’ condition. These assessments will help determine the effectiveness of Risankizumab in managing Psoriatic Arthritis symptoms. The study aims to provide valuable information on whether Risankizumab can be a beneficial treatment option for individuals with this condition, especially for those who have not responded well to other treatments in the past.

1 joining the study

Upon joining the study, a clinical diagnosis of psoriatic arthritis is confirmed. Symptoms must have started at least six months before the screening visit.

Active disease is confirmed at the baseline visit. A diagnosis of active plaque psoriasis with at least one psoriatic plaque of 2 centimeters or more in diameter or nail changes consistent with psoriasis is required.

A history of inadequate response or intolerance to previous biologic or csDMARD therapies is documented.

2 initial treatment phase

Participants receive either risankizumab or a placebo. Risankizumab is administered as a solution for injection in a pre-filled syringe.

The medication is given subcutaneously, which means it is injected under the skin.

The dosage of risankizumab is 150 mg.

3 monitoring and assessment

Participants are monitored for their response to the treatment. The primary goal is to assess the proportion of participants achieving an ACR20 response by Week 24.

Secondary assessments include changes in health questionnaires and the proportion of participants achieving various response levels, such as ACR50 and ACR70, by Week 24.

Additional evaluations include the resolution of specific symptoms like enthesitis and dactylitis.

4 conclusion of the study

The study is estimated to conclude by April 16, 2026.

Final assessments are conducted to evaluate the overall effectiveness and safety of risankizumab compared to the placebo.

Who Can Join the Study?

  • You must have a clinical diagnosis of Psoriatic Arthritis (PsA), which means your doctor has confirmed you have this condition, and your symptoms must have started at least 6 months before the screening visit.
  • You need to meet the Classification Criteria for PsA (CASPAR) at the screening visit. This is a set of guidelines doctors use to confirm PsA.
  • You must have active disease at the start of the study, meaning your PsA symptoms are currently present and noticeable.
  • You should have a diagnosis of active plaque psoriasis, which is a skin condition with red, scaly patches. You need to have at least one psoriatic plaque that is 2 centimeters or larger, or nail changes that are typical of psoriasis, at the screening visit.
  • You must have shown an inadequate response or intolerance to previous treatments, which could include biologic therapies or csDMARD therapies. These are types of medications used to treat PsA.
  • Both male and female participants are eligible to join the study.

Who Cannot Join the Study?

  • Patients who have a different condition than Psoriatic Arthritis cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.
  • Patients who do not meet the specific health requirements set by the study cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario Y Politecnico La Fe Valencia Spain
Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik Bialystok Poland
CENTRUM MEDYCZNE REUMA PARK Warsaw Poland
Katholieke Universiteit te Leuven Leuven Belgium
Unidade Local De Saúde De Santa Maria, E.P.E. Lisbon Portugal

Other Sites

Site Name City Country Status
Universitair Ziekenhuis Gent Gent Belgium
Hospital Universitario 12 De Octubre Madrid Spain
University General Hospital Of Heraklion Heraklion Greece
Instituto Portugues De Reumatologia Lisbon Portugal
MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH Hamburg Germany
Unidade Local De Saude Do Alto Minho E.P.E. Ponte De Lima Portugal
Athens Naval Hospital Athens Greece
Malopolskie Centrum Kliniczne Cracow Poland
Frederiksberg Hospital Frederiksberg Denmark
Universita’ Politecnica Delle Marche Ancona Italy
East Tallinn Central Hospital Tallin Estonia
St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr Herne Germany
MediTrials OÜ Tartu Estonia
University Of Szeged Szeged Hungary
North Estonia Medical Centre Foundation Tallin Estonia
Vital-Medicina Kft. Veszprem Hungary
Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p. Elblag Poland
Cqahxjm Bljuq Krkvvddnjao Pljgtyvf Sff z ozhg Gdansk Poland
Pviw Tkrpf Hwhsyqbz Uqmvyltglcnt Sabadell Spain
Bxgbkqqrsd Iduqykkeihjh Bkigq Ibmjaatqocrbv Kvkowk Budapest Hungary
Cch Hamuuxs Khxw Encs Hungary
Hpiadtnu Upbhnimtjtftz di A Cqkuco A Coruna Galicia Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
11.07.2019
Denmark Denmark
Recruiting
11.07.2019
Estonia Estonia
Not recruiting
11.07.2019
Germany Germany
Not recruiting
11.07.2019
Greece Greece
Not recruiting
11.07.2019
Hungary Hungary
Not recruiting
11.07.2019
Italy Italy
Not recruiting
11.07.2019
Poland Poland
Not recruiting
11.07.2019
Portugal Portugal
Not recruiting
11.07.2019
Spain Spain
Not recruiting
11.07.2019

Trial locations

Investigated drugs:

Risankizumab is a medication being studied for its effectiveness in treating active psoriatic arthritis. It is designed to help reduce the signs and symptoms of this condition, especially in patients who have not responded well to other biological therapies or have experienced side effects from them.

Psoriatic Arthritis – Psoriatic arthritis is a chronic inflammatory condition that affects both the skin and joints. It is associated with psoriasis, a skin disease characterized by red, scaly patches. The disease can cause joint pain, stiffness, and swelling, which may lead to joint damage over time. Symptoms often vary in severity and can affect any joint in the body, including the spine and fingers. The progression of psoriatic arthritis can be unpredictable, with periods of increased symptoms followed by times of remission. It is important to monitor the condition to manage symptoms effectively.

Trial ID:
2023-505477-33-00
Protocol code:
M15-998
NCT ID:
NCT03671148
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Tulisokibart for Psoriatic Arthritis in Adults

    Recruiting

    1
    Investigated drugs:
    Germany Poland Spain

  • A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

    Recruiting

    1
    Czechia Germany Hungary Poland Spain